In our intestines, there are a wide variety of intestinal microorganisms, which are called intestinal microflora. Many studies have proved that they play an extremely important role in maintaining normal digestion and absorption, regulating immunity and preventing pathogen invasion.
"Ct"
-
-
Apparatus
Fujifilm Ai Technology Can Predict Whether Cognitive Disorders Will Progress To Alzheimer's Disease
Fujifilm Corporation and the National Center for Psychiatric and Neurological Research have announced positive research results using Fujifilm's new AI technology to predict whether a patient with mild cognitive impairment (MCI) will progress to Alzheimer's disease (AD) within two years.
-
Medical
New Research Shows Promise For Bone Marrow Transplant Recipient Patients To Reduce Treatment Side Effects!
Researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai have now identified a new treatment that promises to help cancer patients with bone marrow transplants manage side effects better than current standard therapies, making the treatment more effective and safer.
-
Apparatus
Check breast cancer like drinking and driving: breath detector capable of diagnosing various diseases
When it comes to the breath detector, everyone will think of the thing used by the traffic police to check drinking and driving. For those who drink and drive, they will lose their temper when they see the breath detector. In fact, the gas exhaled by the human body has many characteristics. It can not only detect alcohol, but also reflect the health of the human body and detect some diseases. This breath detector introduced in this article can detect breast cancer, diabetes, lung cancer, Parkinson's disease, asthma, schizophrenia, kidney and liver failure and other diseases.
-
On April 4, 2015, the 100-year-old active swimmer Mieko Nagaoka (living in Tabushi Town, Yamaguchi Prefecture, Japan) successfully completed the women's 1500-meter freestyle competition and became the world's first swimmer in the age group of 100-104.
-
Medical
Japanese Scientists Find That Nmn Supplementation May Treat Retinal Dysfunction Caused By Cardiovascular Disease
New research by japanese scientists has found that
-
As more and more organisms become resistant to antibiotics, the threat to human health is increasing. The overuse of antibiotics leads to drug resistance. It is very important to limit the use of antibiotics. The research team of the University of Alberta in Canada has recently developed a hand-held detection instrument, which allows first-line clinicians to distinguish between patients with viral infection or bacterial infection within a few minutes, thus helping to reduce unnecessary antibiotic prescriptions and overuse of antibiotics. Because antibiotics are only effective for bacteria, if the patient is infected with virus, there is no need to prescribe antibiotics.
-
Apparatus
Study Confirms Widespread Presence Of Nectin-4 Target In Head And Neck Cancer, ADC Drug In Play!
Nectin-4 is an important target that has been shown to be available as a treatment for locally advanced and advanced bladder cancer. Based on this, Padcev (enfortumab-vedotin-ejfv), the first ADC drug (antibody-coupled drug) for uroepithelial carcinoma, has also received accelerated FDA approval for the treatment of locally advanced or advanced bladder cancer in patients who have previously received immune checkpoint inhibitors (PD-L1, PD-1) and platinum-containing chemotherapy before surgery (neoadjuvant therapy) or after surgery (adjuvant therapy). Adult patients with advanced or late-stage uroepithelial carcinoma (a common type of bladder cancer).
-
In today's rapidly changing world of science and technology, a research result that sounds very sci-fi will appear from time to time. No, a paper published in the journal Science Robotics belongs to this scope: a cell regeneration robot that successfully works in vivo.
-
Apparatus
Significantly Longer Survival In Refractory Breast Cancer With The Addition Of Eganelisib To Standard Treatment!
Data from a trial show that adding the new drug Eganelisib to standard treatment significantly improves the length of survival for patients with triple-negative breast cancer whose disease remains unexacerbated. Patients benefited regardless of their PD-L1 status.